Mitsubishi UFJ Asset Management Co. Ltd. Purchases 172,017 Shares of DexCom, Inc. (NASDAQ:DXCM)

Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 23.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 909,584 shares of the medical device company’s stock after buying an additional 172,017 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. owned 0.23% of DexCom worth $73,740,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of DXCM. Cerity Partners LLC boosted its holdings in DexCom by 190.0% in the third quarter. Cerity Partners LLC now owns 60,050 shares of the medical device company’s stock worth $4,026,000 after acquiring an additional 39,344 shares in the last quarter. D.A. Davidson & CO. boosted its stake in DexCom by 22.4% in the 3rd quarter. D.A. Davidson & CO. now owns 32,578 shares of the medical device company’s stock worth $2,184,000 after purchasing an additional 5,969 shares in the last quarter. Townsquare Capital LLC grew its position in DexCom by 43.6% during the 3rd quarter. Townsquare Capital LLC now owns 9,568 shares of the medical device company’s stock valued at $641,000 after purchasing an additional 2,905 shares during the last quarter. Freedom Investment Management Inc. increased its stake in DexCom by 10.2% during the 3rd quarter. Freedom Investment Management Inc. now owns 3,035 shares of the medical device company’s stock valued at $203,000 after purchasing an additional 281 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund raised its holdings in DexCom by 127.4% in the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 83,037 shares of the medical device company’s stock worth $5,567,000 after buying an additional 46,527 shares during the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Stock Performance

NASDAQ:DXCM opened at $67.74 on Friday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The stock has a 50-day simple moving average of $82.32 and a two-hundred day simple moving average of $77.01. The firm has a market capitalization of $26.47 billion, a PE ratio of 47.37, a P/E/G ratio of 2.30 and a beta of 1.28. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $141.99.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Analysts forecast that DexCom, Inc. will post 2.03 EPS for the current year.

Analyst Upgrades and Downgrades

DXCM has been the subject of several analyst reports. Canaccord Genuity Group raised their price target on shares of DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a research report on Friday, February 14th. Morgan Stanley lifted their target price on DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a report on Friday, February 14th. Wells Fargo & Company reaffirmed an “overweight” rating on shares of DexCom in a report on Saturday, March 8th. Citigroup lifted their price objective on DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a report on Tuesday, March 4th. Finally, Baird R W upgraded shares of DexCom from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Five analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $99.82.

Insider Buying and Selling

In other DexCom news, CEO Kevin R. Sayer sold 33,359 shares of DexCom stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $2,899,230.69. Following the sale, the chief executive officer now directly owns 319,037 shares in the company, valued at approximately $27,727,505.67. The trade was a 9.47 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Jacob Steven Leach sold 14,076 shares of the stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $990,668.88. Following the transaction, the chief operating officer now directly owns 313,497 shares of the company’s stock, valued at $22,063,918.86. This trade represents a 4.30 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 105,009 shares of company stock valued at $8,044,178. Company insiders own 0.30% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.